Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD.

Cassandra Kimber,Shiqin Zhang,Cassandra Johnson,Raymond E West,Alexander J Prokopienko,Jonathan D Mahnken,Alan S Yu,Andrew N Hoofnagle,Diana Ir,Charles E Robertson,Makoto Miyazaki,Michel Chonchol,Anna Jovanovich,Bryan Kestenbaum,Daniel N Frank,Thomas D Nolin,Jason R Stubbs

Kidney360（2020）

引用 10|浏览65

暂无评分

摘要

Rifaximin Therapy in Chronic Kidney Disease, NCT02342639.

查看译文

关键词

chronic kidney disease, cardiovascular disease, chronic renal insufficiency, clinical trial, gastrointestinal microbiome, gut microbiome, indoxyl sulfate, inflammation, p-cresol sulfate, rifaximin, TMAO, uremia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要